- Home
- NEWTP vs VIR Comparison
NEWTP vs VIR Comparison
Compare NEWTP & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWTP
- VIR
- Stock Information
- Founded
- NEWTP N/A
- VIR 2016
- Country
- NEWTP United States
- VIR United States
- Employees
- NEWTP N/A
- VIR N/A
- Industry
- NEWTP Major Banks
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- NEWTP Finance
- VIR Health Care
- Exchange
- NEWTP Nasdaq
- VIR Nasdaq
- Market Cap
- NEWTP 635.7M
- VIR 706.4M
- IPO Year
- NEWTP N/A
- VIR 2019
- Fundamental
- Price
- NEWTP $24.08
- VIR $5.14
- Analyst Decision
- NEWTP
- VIR Strong Buy
- Analyst Count
- NEWTP 0
- VIR 10
- Target Price
- NEWTP N/A
- VIR $26.80
- AVG Volume (30 Days)
- NEWTP N/A
- VIR 1.7M
- Earning Date
- NEWTP N/A
- VIR 10-30-2025
- Dividend Yield
- NEWTP N/A
- VIR N/A
- EPS Growth
- NEWTP N/A
- VIR N/A
- EPS
- NEWTP N/A
- VIR N/A
- Revenue
- NEWTP N/A
- VIR $19,000,000.00
- Revenue This Year
- NEWTP N/A
- VIR N/A
- Revenue Next Year
- NEWTP N/A
- VIR $9.65
- P/E Ratio
- NEWTP N/A
- VIR N/A
- Revenue Growth
- NEWTP N/A
- VIR N/A
- 52 Week Low
- NEWTP N/A
- VIR $4.16
- 52 Week High
- NEWTP N/A
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- NEWTP N/A
- VIR 54.91
- Support Level
- NEWTP N/A
- VIR $4.86
- Resistance Level
- NEWTP N/A
- VIR $5.82
- Average True Range (ATR)
- NEWTP 0.00
- VIR 0.31
- MACD
- NEWTP 0.00
- VIR 0.12
- Stochastic Oscillator
- NEWTP 0.00
- VIR 56.69
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.